Dearborn Partners LLC lowered its stake in STERIS plc (NYSE:STE - Free Report) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,815 shares of the medical equipment provider's stock after selling 1,302 shares during the period. Dearborn Partners LLC owned 0.13% of STERIS worth $26,068,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Geode Capital Management LLC increased its position in STERIS by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,303,625 shares of the medical equipment provider's stock valued at $556,786,000 after acquiring an additional 17,007 shares during the period. Principal Financial Group Inc. grew its holdings in STERIS by 0.5% during the 4th quarter. Principal Financial Group Inc. now owns 1,119,643 shares of the medical equipment provider's stock worth $230,160,000 after acquiring an additional 5,419 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of STERIS during the 4th quarter worth approximately $223,987,000. Franklin Resources Inc. lifted its position in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock valued at $191,370,000 after acquiring an additional 529,308 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in STERIS by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 569,837 shares of the medical equipment provider's stock valued at $117,136,000 after purchasing an additional 18,384 shares in the last quarter. Institutional investors own 94.69% of the company's stock.
STERIS Stock Down 0.9 %
Shares of NYSE:STE traded down $2.07 during mid-day trading on Thursday, hitting $222.39. 419,169 shares of the company traded hands, compared to its average volume of 528,583. The stock has a 50-day moving average price of $218.71 and a two-hundred day moving average price of $222.64. STERIS plc has a 12-month low of $197.82 and a 12-month high of $248.24. The stock has a market cap of $21.85 billion, a P/E ratio of 47.22 and a beta of 0.92. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32.
STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, equities research analysts forecast that STERIS plc will post 9.08 earnings per share for the current year.
STERIS Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS's payout ratio is 48.41%.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the company. Stephens reiterated an "overweight" rating and issued a $240.00 price target on shares of STERIS in a report on Thursday, February 6th. JMP Securities restated a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a report on Thursday, February 6th. Finally, Piper Sandler raised their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $258.75.
Get Our Latest Stock Analysis on STE
STERIS Company Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Articles
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
